ResearcherAsan Medical CenterNo recent work listed
Eun Ah Choi
Matched on OpenAlex author ID A5102347116. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper
Papers 3
- Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Co-author DOI 10.1073/pnas.2119048119↗
- A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1016/j.canlet.2019.08.002↗
- A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer c… Co-author DOI 10.1002/1878-0261.12364↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Suhwan Chang · 3 shared papers, 2018–2022 · strength 0.32
- Paper Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. DOI 10.1073/pnas.2119048119↗
- Paper A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic duct… DOI 10.1016/j.canlet.2019.08.002↗
- Paper A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective… DOI 10.1002/1878-0261.12364↗
- Song Cheol Kim · 3 shared papers, 2018–2022 · strength 0.32
- Paper Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. DOI 10.1073/pnas.2119048119↗
- Paper A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic duct… DOI 10.1016/j.canlet.2019.08.002↗
- Paper A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective… DOI 10.1002/1878-0261.12364↗
- Yeon‐Sook Choi · 2 shared papers, 2018–2022 · strength 0.20
- Yeon Wook Kim · 1 shared paper, 2022 · strength 0.12
- Mi‐Ju Kim · 1 shared paper, 2022 · strength 0.12
- Seung‐Mo Hong · 1 shared paper, 2022 · strength 0.12
- Jae Yun Jung · 1 shared paper, 2022 · strength 0.12
- Inki Kim · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.